Amundi Mirati Therapeutics, Inc. Transaction History

Amundi

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $2.26 Million - $3.36 Million	53,915 Added 492.01%	64,873 $3.81 Million
Q3 2023 Nov 14, 2023	SELL	$27.8 - $45.35 $78,173 - $127,524	-2,812 Reduced 20.42%	10,958 $477,000
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $632,347 - $866,173	-17,502 Reduced 55.97%	13,770 $497,000
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $1.01 Million - $1.5 Million	27,676 Added 769.63%	31,272 $1.16 Million
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $35,285 - $84,320	-855 Reduced 19.21%	3,596 $162,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $214,319 - $312,293	3,602 Added 424.26%	4,451 $313,000
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $33,246 - $75,314	849 New	849 $51,000
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $5.48 Million - $10.9 Million	-72,330 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $465,335 - $670,772	-3,525 Reduced 4.65%	72,330 $8.59 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $4.1 Million - $5.51 Million	-31,041 Reduced 29.04%	75,855 $13.4 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $15.4 Million - $19.2 Million	106,896 New	106,896 $17.3 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

Stay updated on Amundi with notifications on news.